The content on this site is intended for healthcare professionals only
Soft tissue sarcomas present significant challenges in diagnosis and treatment due to having over 100 types. Current trials often combine different sarcoma types to gather data.
Tyrosine kinase inhibitors show promise, especially when paired with anthracyclines. New treatment combinations are needed due to existing therapies' toxicity.
Targeted therapies, including trastuzumab deruxtecan, and gamma secretase inhibitors for desmoid tumours are explored, highlighting the need for subtype-specific therapies for better patient outcomes.
Clinical advances in cancer molecular testing: the patient's perspective
Advancements in gastrointestinal cancer treatments at ASCO 2025
Future of chemotherapy and targeted therapies
Burden and trends of breast cancer worldwide: Opportunities for prevention?
Understanding Zimbabwe's pharmacovigilance system
Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC
Enhancing medicine safety monitoring in Zambia
Understanding pharmacovigilance challenges in Lesotho & Swaziland
Predicting tumour mutations from pathology images may help increase personalised medicine utilisation
